Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06493448Not Yet Recruiting

Prospective Observational Cohort Study

Role: lead

NCT06390748Phase 2Completed

Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes

Role: lead

NCT06379568Completed

Risk of Aspergillus Infection in Patients With Chronic Lung Disease

Role: lead

NCT06333379Completed

Aspergillosis Detection Via EBC-GM in Ventilated Patients

Role: lead

NCT06284746Phase 2Recruiting

Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer

Role: lead

NCT05334849Completed

Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy

Role: lead

NCT05397548Unknown

Use of Circulating Exosomal LncRNA-GC1 to Monitor Gastric Cancer

Role: lead

NCT01583361Phase 3Unknown

SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer

Role: lead

All 8 trials loaded